Investing

Compugen : CGEN

CGEN

Stock Data

$2.83

$0.24 (9.27%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Compugen Ltd is a pioneer in the field of therapeutic discovery and development, focusing on immuno-oncology treatments. With a robust pipeline that includes treatments for solid tumors, advanced malignancies, and specific cancers like non-small cell lung cancer and head and neck squamous cell carcinoma, Compugen is at the forefront of developing innovative antibodies. The company collaborates with industry giants such as Bayer Pharma AG, Bristol-Myers Squibb, and AstraZeneca, and engages in cutting-edge research with Johns Hopkins School of Medicine. Founded in 1993 and based in Holon, Israel, Compugen is dedicated to advancing cancer treatment through groundbreaking research.

Latest Activity

CGENCompugen

Q2 2026

Aug 3, 7:02am ET

EPS

-$0.07

est -$0.09+$0.01

Revenue

$3M

est $1M+102.6%

Compugen doubled revenue expectations on Gilead milestone payments, extending cash runway into 2029 while awaiting a potential make-or-break clinical readout on COM701 in early 2027.

ShareRead more

All Compugen Articles

0 Articles

No articles found for Compugen.